Functional and immunological characterization of a duffy binding-like alpha domain from Plasmodium falciparum Erythrocyte membrane protein 1 that mediates rosetting by Mayor, Alfredo et al.
INFECTION AND IMMUNITY, Sept. 2009, p. 3857–3863 Vol. 77, No. 9
0019-9567/09/$08.000 doi:10.1128/IAI.00049-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Functional and Immunological Characterization of a Duffy
Binding-Like Alpha Domain from Plasmodium falciparum
Erythrocyte Membrane Protein 1 That
Mediates Rosetting
Alfredo Mayor,1,2,3* Eduard Rovira-Vallbona,1 Anand Srivastava,2 Surya K. Sharma,4
Sudhanshu S. Pati,5 Laura Puyol,1 Llorenç Quinto,1 Quique Bassat,1,3
Sonia Machevo,3 Inacio Mandomando,3 Virander S. Chauhan,2
Pedro L. Alonso,1,3 and Chetan E. Chitnis2
Barcelona Centre for International Health Research (CRESIB), Hospital Clínic/Institut d’Investigacions Biome`diques August Pi i
Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain1; International Centre for Genetic Engineering and Biotechnology,
Aruna Asaf Ali Marg, New Delhi, India2; Manhic¸a Health Research Centre (CISM), Maputo, Mozambique3;
National Institute of Malaria Research (formerly Malaria Research Centre), Field Station, Sector 5,
Rourkela, District Sundargarh, Orissa, India4; and Ispat General Hospital,
Rourkela, District Sundargarh, Orissa, India5
Received 15 January 2009/Returned for modification 12 February 2009/Accepted 5 June 2009
The Duffy binding-like (DBL) domains are common adhesion modules present in Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP1) variants, which are responsible for immune evasion and cytoad-
herence. Knowledge about how immune responses are acquired against polymorphic DBL domains of PfEMP1
can aid in the development of vaccines for malaria. A recombinant DBL domain, encoded by R29 var1, which
binds complement receptor 1 to mediate rosetting by the P. falciparum laboratory strain R29, was expressed in
Escherichia coli, renatured by oxidative refolding to its native form, and purified to homogeneity. Antibody
levels in 704 plasmas obtained from residents of areas of different levels of malaria endemicity in Orissa
(India) and Manhic¸a (Mozambique) were assessed by enzyme-linked immunosorbent assay. The refolded
DBL domain was pure, homogeneous, and functional in that it bound human erythrocytes with specificity and
was capable of inhibiting rosetting. The proportion of individuals who had measurable anti-DBL immuno-
globulin G responses was low in areas of low malaria endemicity in Orissa (6.7%) but high in areas of high
endemicity in Orissa (87.5%) and Manhic¸a (74.5%). Seroprevalence and antibody levels against the recombi-
nant protein increased with the age of inhabitants from areas with high transmission rates (P < 0.001). Half
of the children in these areas had seroconverted by the age of 5 years. These findings suggest that in spite of
the extreme polymorphism of PfEMP1 DBL domains, the acquisition of specific antibodies is rapid and age
related and reflects the reduced risk of malaria in areas with high transmission rates. Further studies are
required to elucidate the role of these antibodies in protection from malaria.
Individuals residing in areas where Plasmodium falciparum
malaria is endemic gradually develop clinical immunity with
age following repeated infections (17). Passive transfer exper-
iments have shown that immunoglobulin G (IgG) antibodies
play a major role in the mechanisms of protection against
malaria (9, 10). Naturally acquired IgGs with specificity for
variant surface antigens (VSA) expressed on the surfaces of P.
falciparum-infected erythrocytes (IE) are believed to contrib-
ute to the regulation of parasite densities in a manner that
decreases the incidence of clinical disease (4, 13, 15, 19).
The most studied VSA, P. falciparum erythrocyte membrane
protein 1 (PfEMP1), is a family of large (250 to 350 kDa) (2),
polymorphic proteins that are encoded in each parasite ge-
nome by 60 different var genes (12). Switches in var gene
expression allow parasites to evade host immunity (18).
PfEMP1 mediates the binding of IE to host endothelial cell
receptors, to uninfected erythrocytes to mediate rosetting, and
to platelets to form clumps of IE enabling sequestration of the
parasite at different sites in the host (21). Sequestration in
some internal organs has been implicated in progression to
severe disease manifestations, such as cerebral and placental
malaria (23).
PfEMP1 proteins are composed of a variable number of
adhesive domains of two types, namely, Duffy binding-like
(DBL) domains and cysteine-rich interdomain regions (34).
DBL sequences are extremely polymorphic, probably reflect-
ing the intensity of immune pressure on PfEMP1 proteins at
the IE surface. Although these domains average 50% amino
acid identity (11), they can still be classified into six different
types (, , , , ε, and X) based on the presence of conserved
sequence motifs, including disulfide-linked cysteines (34). Cer-
tain DBL domains harbor adhesive functions associated with
virulent phenotypes. It has been shown that the DBL domain
is involved in the formation of rosettes (7, 31), a cytoadhesion
phenotype that is associated with cerebral malaria (5, 23, 30,
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36). The DBL domain encoded by R29 var1, the var gene
expressed by the rosetting parasite R29, binds complement
receptor 1 (CR1) on erythrocytes to mediate the formation of
rosettes (31). The CR1 binding residues map to the 233-amino-
acid central stretch of the DBL domain (20).
Current research efforts seek to determine whether specific
PfEMP1 variants containing related adhesive domains with
conserved structures are associated with severe disease. Such
conserved adhesion-related protein structures could then be
targeted therapeutically or prophylactically across parasite iso-
lates to protect against severe malaria. The association be-
tween naturally acquired antibodies against VSA (4, 13, 19),
which are dominantly represented by PfEMP1 molecules, and
protection against clinical malaria in regions of endemicity
argues for the inclusion of PfEMP1 domains in the develop-
ment of malaria vaccines. Despite this apparent role in the
development of antimalarial immunity, the use of PfEMP1 in
vaccine development is hampered by the extensive polymor-
phism in the var gene family. Nevertheless, evidence support-
ing the utilization of the DBL domain as a vaccine candidate
is accumulating (8, 22). DBL is an attractive candidate be-
cause it is one of the most conserved domains of PfEMP1 (11).
Understanding naturally acquired immune responses to DBL
can aid in the development of malaria vaccines based on this
domain.
Here we describe methods to produce the central, functional
region of the R29 var1-encoded DBL domain in its correctly
folded conformation. The recombinant DBL (rDBL) do-
main was used to assess the presence of naturally acquired
anti-DBL antibodies in plasma samples collected from indi-
viduals residing in areas of different levels of endemicity in
India and Mozambique. We show that individuals from areas
with high rates of malaria transmission rapidly develop anti-
bodies against DBL as a function of age.
MATERIALS AND METHODS
Expression of rDBL. The binding site of the R29 var1-encoded DBL do-
main has been mapped to the central region including amino acids 133 to 366
(Cys residues 5 to 12) (20). A DNA fragment (nucleotides 399 to 1098) encoding
R29 DBL (20, 31) fused to a hexahistidine tag at the C-terminal end was
amplified by a PCR using primers 5-GCA TGC CAT GGA TAG AAA TTT
AGA ATA TTT GAT C-3 and 5-CGA GTG TCG ACT CAG TGA TGG TGA
TGG TGA TGA CGT GGA CAA TTT AAA TCT ATA AAG-3, with a
plasmid containing a DNA fragment encoding DBL of P. falciparum R29 as the
template. The PCR product was cloned into Escherichia coli expression vector
pET28a() (Novagen). The insert as well as junctions between the vector and
insert was sequenced using an ABI 310 automated DNA sequencer (Applied
Biosystems). E. coli BL21(DE3) cells (Novagen) were transformed with the
construct and used for expression of rDBL by induction with 1 mM isopropyl-
-D-thiogalactopyranoside (IPTG). After 4 h of growth at 37°C, E. coli cells were
harvested and lysed by sonication, and inclusion bodies were collected by
centrifugation and solubilized in 10 mM Tris, pH 8.0, containing 6 M guanidine-
hydrochloride. rDBL was purified from solubilized inclusion bodies under de-
naturing conditions by metal-affinity chromatography using a nickel-nitrilotri-
acetic acid column as described by the manufacturer (Qiagen). The column was
washed with equilibration buffer at pH 6.3, and bound protein was eluted with
elution buffer at pH 4.3.
Refolding of rDBL. Purified, denatured rDBL was refolded by 100-fold
dilution in a buffer containing 50 mM phosphate buffer, pH 6.5, 2 mM cysteine,
0.67 mM cystamine dihydrochloride, 16 mM -cyclodextrin, 0.4 mM Triton
X-100, 1 M urea, and 0.5 M arginine at a final concentration of recombinant
protein of 60 mg/ml. Refolding was allowed to proceed for 36 h at 10°C. The
refolding solution was dialyzed for 48 h against dialysis buffer (50 mM phosphate
buffer, pH 6, 1 M urea) to remove arginine. Refolded rDBL was loaded on an
SP-Sepharose column (Pharmacia) equilibrated with 50 mM phosphate buffer,
pH 6, and the bound protein was eluted with a linear gradient of NaCl (100 mM
NaCl to 1 M NaCl). Fractions containing refolded rDBL were pooled, and
rDBL was further purified by gel filtration chromatography using a preparative-
grade Superdex 75 column (Pharmacia) with 50 mM phosphate buffer, pH 6.0,
containing 150 mM NaCl as the running buffer. Refolded rDBL was separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) be-
fore and after reduction with -mercaptoethanol and was detected by Coomassie
blue and silver staining.
Analysis of refolded rDBL by reverse-phase chromatography. Refolded
rDBL was loaded on a reverse-phase C8 column. The gradient used for elution
was developed using buffer A (0.05% trifluoroacetic acid in water) and buffer B
(0.05% trifluoroacetic acid in 90% acetonitrile and 10% water). The column was
initially equilibrated with 95% buffer A and 5% buffer B and reached a compo-
sition of 90% buffer A and 10% buffer B in 10 min and a final composition of 5%
buffer A and 95% buffer B in another 30 min.
Functional characterization of refolded rDBL. Blood collected in 10% ci-
trate phosphate dextrose was washed three times in RPMI 1640. Ten micrograms
of rDBL was incubated for 1 h at room temperature with 2 	 108 normal
erythrocytes or human erythrocytes expressing low levels of CR1 (kindly pro-
vided by Karina Yazdanbaksh, New York Blood Centre, New York, NY) in a
final volume of 600 
l of RPMI 1640 containing 1% fetal calf serum. The
reaction mixture was layered over dibutylphthalate (Sigma) and centrifuged to
collect erythrocytes. Bound protein was eluted from the erythrocytes with 300
mM NaCl, separated by SDS-PAGE, and detected by Western blotting using a
mouse monoclonal antibody against pentahistidine (Qiagen). Plasmodium vivax
region II (PvRII) of the Duffy binding protein, which was previously shown to
bind Duffy antigen receptor for chemokines on erythrocytes by this method (33),
was used as a positive control. The intensities of the bands were quantified by
densitometry scanning.
Rosette reversal by rDBL. A P. falciparum R29 culture at 5% parasitemia
and with a rosetting frequency of 60 to 70% was stained with 20 
g/ml ethidium
bromide for 5 min at 37°C, washed twice with incomplete RPMI 1640, and
resuspended at 4% hematocrit in complete RPMI with 10% heat-inactivated
human serum. Twenty-five microliters of parasite suspension was incubated at
37°C for 30 min with doubling concentrations of rDBL (0.4 
g/ml to 200 
g/ml)
in a final volume of 50 
l. The frequency of rosette formation was assessed by
fluorescence microscopy in triplicate experiments. Two hundred infected eryth-
rocytes were counted in each experiment, with the binding of two or more
uninfected erythrocytes constituting a rosette. Rosetting at each rDBL concen-
tration was expressed as a percentage of the rosetting frequency in control R29
cultures with no added protein. The same amounts of PvRII were used as a
negative control.
Study areas and subjects. Individuals were enrolled for the study at Sundar-
garh District in Orissa (Eastern India) in March 2004 and at Manhic¸a District
(Southern Mozambique) in 2007. The characteristics of the areas have been
described in detail elsewhere (16, 32). Briefly, Sundargarh District is character-
ized by variations in transmission patterns over short geographic distances. The
annual incidence of malaria cases per 1,000 persons is higher in villages located
in forested areas (284.1) than in villages located in deforested plain areas (31.2)
(32). The estimated entomological inoculation rate (EIR) in 2001 to 2003 was
113.5 infective bites per person per year in forest areas and 5.1 infective bites per
person per year in plain areas (32). Manhic¸a District is characterized by peren-
nial malaria transmission, mostly attributable to P. falciparum, with some sea-
sonality. The estimated EIR in 2002 was 38 infective bites per person per year
(1). In Sundargarh District, 539 volunteers (434 people from three forest villages
[San Dulakudar, Rangamati, and Benuam] and 105 people from two plain
villages [Chikatmati and Bhalupatra]) aged 1 to 84 years were enrolled in the
survey. In Manhic¸a District, 60 children (aged 1 to 5 years) and 105 adults (aged
15 to 73 years) attending the Manhic¸a District Hospital with signs and symptoms
of malaria were enrolled. Plasmas were isolated from heparin-anticoagulated
blood samples. Parasitemic persons were treated following national guidelines at
the time of the study. All study participants or their parents or guardians gave
informed consent. The study protocol was approved by the ethical committee of
the National Institute of Malaria Research, Indian Council of Medical Research,
New Delhi, India, the National Mozambican Ethics Review Committee, and the
Hospital Clinic of Barcelona Ethics Review Committee.
Measurement of antibodies against rDBL by ELISA. IgG levels in the col-
lected plasmas were determined by an enzyme-linked immunosorbent assay
(ELISA). MaxiSorp immunoplates (Nunc) were coated with 200 ng per well of
rDBL in 0.05 M carbonate-bicarbonate buffer by overnight incubation at 4°C.
Plates were washed with 0.05% Tween 20 in phosphate-buffered saline (PBS-
Tween), blocked with 2% bovine serum albumin in PBS-Tween for 8 h at 4°C,
3858 MAYOR ET AL. INFECT. IMMUN.
and washed with PBS-Tween, and plasma samples (1:200) were added in dupli-
cate, along with a positive control plasma (a pool of plasmas from eight adults
with lifelong exposure to malaria) and 10 negative control plasmas from nonex-
posed European adults. Plates were incubated overnight at 4°C, washed, and
incubated for 1 h with peroxidase-conjugated goat anti-human IgG secondary
antibodies (Sigma, St. Louis, MO) at a dilution of 1:30,000. After washing of the
plates three times with PBS-Tween, 100 
l of a phosphate solution with 0.012%
H2O2 substrate and o-phenylenediamine was added to each well. The colorimet-
ric reaction was stopped with 25 
l of 3 M H2SO4 after 5 min, and the optical
density (OD) was measured at 492 nm. Plasmas from Manhic¸a were also tested
at a 1:200 dilution for IgG recognition of merozoite surface protein 1 (MSP-119;
19-kDa fragment, from strain 3D7), erythrocyte-binding antigen 175 (EBA-175;
region F2, from strain CAMP), and apical membrane antigen 1 (AMA-1; full
ectodomain, from strain 3D7) produced in E. coli following similar procedures to
those for rDBL. Antibody responses were expressed in arbitrary units (AU) to
account for day-to-day variation and were calculated as follows: (ODsample/
ODpositive control) 	 100. The cutoff for positivity was defined as the AU value 3
standard deviations above the arithmetic mean for the negative control plasmas
(33.0 for DBL, 53.3 for MSP-1, 31.1 for EBA-175, and 20.3 for AMA-1).
Statistical analysis. Mean rosetting frequencies at different rDBL concen-
trations were compared to the rosetting frequency in control R29 cultures with
no added protein by using Student’s t test. Fisher’s test was used to compare
proportions of antibody responders in different age groups (1 to 2.5, 2.5 to 5, 5
to 7.5, 7.5 to 15, 15 to 25, 25 to 35, and 35 years), whereas the differences in the
immunoglobulin levels (AU) were compared using the Kruskal-Wallis test. P
values of 0.05 were considered to indicate statistical significance.
RESULTS
Biochemical, biophysical, and functional characterization of
refolded and purified rDBL. rDBL expressed in E. coli
accumulates in inclusion bodies as insoluble aggregates. Mis-
folded rDBL was solubilized in 6 M guanidine-HCl, purified
under denaturing conditions by metal-affinity chromatography,
and refolded by the method of rapid dilution. Cysteine and
cystamine were used to allow disulfide bond shuffling during
refolding. Conditions such as the concentration of rDBL and
pH were optimized to maximize yields of refolded rDBL.
Ion-exchange chromatography using an SP-Sepharose column
and gel filtration chromatography using a Superdex 75 column
were used to purify rDBL monomers to homogeneity after
they refolded. rDBL was separated by SDS-PAGE and de-
tected by Coomassie blue (Fig. 1A) and silver (Fig. 1B) stain-
ing. rDBL migrated with an apparent molecular mass of 27
kDa in denaturing SDS-PAGE gels, as predicted by the calcu-
lated molecular mass of DBL. Densitometry scanning of sil-
ver-stained SDS-PAGE gels indicated that the purity of re-
folded rDBL was 95%. Refolded rDBL migrated slower
in SDS-PAGE gels after reduction with -mercaptoethanol,
indicating the presence of disulfide bonds (Fig. 1A). The mo-
bility of purified rDBL in a Superdex 75 column was consis-
tent with an apparent molecular mass of 27 kDa (data not
shown), indicating that purified rDBL does not contain ag-
gregates or multimers. Refolded rDBL eluted in a single,
symmetric peak by reverse-phase chromatography on a C8
column, suggesting that purified rDBL is conformationally
homogeneous (Fig. 1C).
Erythrocyte binding assays were used to test the functional
activity of refolded rDBL. After incubation of refolded
rDBL with normal or CR1-deficient human erythrocytes to
allow binding, bound protein was eluted, separated by SDS-
PAGE, and detected by Western blotting using a monoclonal
antibody against pentahistidine (Fig. 2). Refolded rDBL
bound to normal human erythrocytes. Densitometry scanning
showed that binding of rDBL to CR1-deficient erythrocytes
was reduced 60% compared to binding to normal erythrocytes,
whereas binding of PvRII to normal and CR1-deficient eryth-
rocytes was similar (Fig. 2).
FIG. 1. Refolded and purified rDBL minimal domain. (A) Mobility
of refolded and purified DBL by SDS-PAGE before and after reduction
with -mercaptoethanol (-ME). (B) Silver-stained SDS-PAGE gel of
refolded and purified rDBL. Different quantities (0.5, 1.0, 1.5, and 2.0

g) of refolded and purified rDBL were reduced, denatured, separated
by SDS-PAGE, and detected by silver staining. (C) Reverse-phase chro-
matography profile of refolded and purified rDBL.
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The ability of rDBL to reverse rosetting of P. falciparum
R29 was also tested. rDBL reversed rosetting of P. falciparum
R29 in a dose-dependent manner (Fig. 3). The rosetting fre-
quency in the absence of rDBL was 58% (standard deviation,
3%), whereas the rosetting frequency in the presence of 200

g/ml of rDBL was 11.3% (standard deviation, 3.1%). Dif-
ferences in rosetting frequency were statistically significant be-
tween control parasites with no added protein and parasites
incubated with a minimum of 6.25 
g/ml rDBL (P  0.01).
No statistically significant reversal of rosetting was observed
with similar amounts of PvRII (Fig. 3).
Recognition of rDBL by plasmas from individuals residing
in areas where P. falciparum is endemic. There were marked
differences among the three study areas with respect to the
proportion of individuals who had measurable anti-rDBL
IgG responses (Table 1). Seropositivity for rDBL was signif-
icantly higher for residents in the forest villages of the Sundar-
garh District in Orissa (380/434 samples; 87.5%) than for res-
idents in deforested plain areas of the Sundargarh District
(7/105 samples; 6.7%) with lower malaria transmission rates
(P 0.001). Similarly, the level of anti-rDBL IgGs was higher
for the population from forest areas in Orissa than for those in
plain villages (Fig. 4) (P  0.001). In plain villages, no statis-
tically significant difference between age groups was observed
in recognition of rDBL (Table 1) or in the level of IgGs (Fig.
4). However, in the population from forest villages, rDBL
IgG seroprevalence (Table 1) and levels of antibodies (Fig. 4)
increased with age. Compared to the youngest children (1 to
2.5 years), the prevalence of rDBL IgG was similar for 2.5- to
5-year-old children (P 0.371) and increased significantly in 5-
to 7.5-year-old children (P  0.018). In Manhic¸a (Mozam-
bique), average recognition was 74.5% (123/165 samples) for
rDBL, 53.9% (89/165 samples) for MSP-1, 59.3% (98/165
samples) for EBA-175, and 84.8% (140/165 samples) for
AMA-1 (Table 1). The prevalence of seropositive individuals
(Table 1) and the level of antibodies (Fig. 5) were found to
increase with age for rDBL, EBA-175, and AMA-1 but not
for MSP-1 (Table 1; Fig. 5). Compared to the youngest chil-
dren (1 to 2.5 years), the first significant increase in antibody
levels was found at 2.5 to 5 years for rDBL (P  0.004) and
at 15 to 25 years for AMA-1 and EBA-175 (P 0.001) (Fig. 5).
Similarly, seroprevalences for rDBL were significantly higher
in 2.5- to 5-year-old Mozambican children (53.3%) than in the
youngest children (16.7%; P  0.006), whereas seropreva-
lences were found to increase later in life (15 to 25 years) for
AMA-1 (P  0.001) and EBA-175 (P  0.003).
DISCUSSION
Here we report methods to produce the minimal functional
domain of DBL encoded by R29 var1 in its correctly folded
conformation. Our results confirm that the region of DBL
required by P. falciparum R29 to mediate rosetting maps to the
central 233-amino-acid region of DBL encoded by R29 var1,
which includes cysteines 5 to 12 (20). Refolded E. coli DBL is
pure, homogeneous, and functional. First, the purity of DBL
was 95%, as determined by densitometry scanning of silver-
stained SDS-PAGE gels. Second, refolded E. coli DBL eluted
in a single peak during reverse-phase chromatography on a C8
column, confirming that it was composed of a homogeneous
population of conformers. Third, the migration profile of re-
folded DBL by gel filtration chromatography indicates that it
is monomeric. Fourth, DBL exhibited a reduction-sensitive
shift in mobility by SDS-PAGE, indicating that intramolecular
disulfide bonds had formed. Fifth, rDBL bound specifically to
CR1, as CR1-deficient erythrocytes bound the recombinant
protein less efficiently than normal erythrocytes did, indicating
that rDBL was folded in its functional conformation. Binding
to CR1-deficient erythrocytes was not null, as the copy number
of CR1 on CR1-deficient erythrocytes is 10 to 20% that on
normal erythrocytes (K. Yazdanbaksh, personal communica-
tion). Finally, we have shown that rDBL is capable of revers-
ing rosette formation in a dose-dependent manner. This is in
contrast to a previous study (25) showing that bacterially pro-
duced DBL domains were unable to disrupt rosettes. This
discrepancy suggests that recombinant proteins produced
through denaturation of inclusion bodies may not reflect the
FIG. 2. Erythrocyte binding assay of refolded and purified rDBL
with CR1-deficient human erythrocytes (lane 1) and normal human
erythrocytes (lane 2). Lanes 4 and 5 show the erythrocyte binding assay
of PvRII with CR1-deficient and normal erythrocytes, respectively.
Lane 3 shows rDBL (1 
g).
FIG. 3. Dose-dependent inhibition of R29 rosetting by rDBL.
Rosetting at each DBL concentration (continuous line) is expressed
as the percentage of rosette frequency compared to that for control
strain R29 with no added protein. PvRII (discontinuous line) was used
as a negative control. Data shown are means and standard deviations
for triplicate experiments with each concentration. Values that are
statistically different from the control value by Student’s t test are
asterisked (*, P  0.001; **, P  0.01; ***, P  0.05).
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correct conformation and that methods to refold the recombi-
nant protein are needed to obtain functional DBL domains
(3, 33).
Recombinant refolded DBL was recognized by plasmas
from individuals residing in regions of India and Mozambique
with high rates of malaria transmission, indicating that DBL
contains B-cell epitopes that are naturally exposed to the host
immune system. In the Manhic¸a population, IgGs against
MSP-1 were found to be the least seroprevalent (53.9%), fol-
lowed by IgGs against EBA-175 (59.3%), DBL (74.5%), and
AMA-1 (84.8%). This is in the range of previously reported
seroprevalences of IgGs against recombinant merozoite anti-
gens (26–29) and DBL domains (24) in areas of malaria
endemicity. Major differences in the acquisition of DBL-
specific antibodies were observed between different malaria
transmission settings. A significant proportion (75 to 87%) of
individuals living in areas with high rates of malaria transmis-
sion in India (EIR, 110 infective bites per person per year) and
Mozambique (EIR, 38 infective bites per person per year) had
developed antibodies directed against DBL. However, resi-
dents of an area in India with a low rate of malaria transmis-
sion (EIR, 5 infective bites per person per year) showed poor
recognition of rDBL (seroprevalence of 6.7%). This is in
accordance with a previous report (24) showing a strong cor-
relation between the immune status of plasma donors and
reactivity with rDBL domains. In the areas with high rates of
transmission, the proportion of rDBL IgG-seropositive re-
sults increased significantly with age, similar to what was ob-
served in Manhic¸a and other African settings for AMA-1 (35)
and EBA-175 (27) but not for MSP-1 (26). However, increases
in IgGs during the first 5 years of life were more accentuated
for DBL than for AMA-1 and EBA-175, as only rDBL IgG
levels and prevalences were found to increase significantly dur-
ing early childhood. Seroconversion against DBL was found
to occur later in the population from forest areas of Orissa (5
to 7.5 years) than in inhabitants from Manhic¸a (2.5 to 5 years),
but this may have been due to the small number of young
Indian children included in the study (n  23), which might
have reduced the power of the comparisons. The age-related
buildup of antibodies to DBL in areas with high rates of
transmission is presumably due to repeated exposure to infec-
tion by P. falciparum. It is interesting that the age at which
children acquire antibodies against DBL coincides with the
age at which clinical immunity would be predicted to occur in
FIG. 4. ELISA reactivity (AU) against rDBL by age group in forest and plain villages of Orissa (India). Continuous lines represent the
medians, and discontinuous lines represent the 25th and 75th percentiles. The areas of the circles are proportional to the numbers of observations.
TABLE 1. Proportions of IgG responders against rDBL, MSP-1, EBA-175, and AMA-1 for forest and plain villages in Orissa (India) and
Manhic¸a (Mozambique)a
Age group (yr)
Orissa plain Orissa forest Manhic¸a
n No. (%) of respondersto rDBL n
No (%) of responders
to rDBL n
No. (%) of responders
rDBL MSP-1 EBA-175 AMA-1
1–2.5 7 0 (0) 6 2 (33.3) 30 5 (16.7) 15 (50.0) 10 (33.3) 20 (66.7)
2.5–5 20 0 (0) 17 10 (58.8) 30 16 (53.3) 17 (56.7) 14 (46.7) 22 (73.3)
5–7.5 15 1 (6.7) 33 28 (84.8)
7.5–15 28 4 (14.3) 170 150 (88.2)
15–25 9 0 (0) 36 33 (91.2) 54 53 (98.1) 27 (50.0) 37 (68.5) 51 (94.4)
25–35 8 0 (0) 62 57 (91.9) 24 23 (95.8) 11 (45.8) 15 (62.5) 21 (87.5)
35 18 2 (11.1) 110 100 (90.9) 27 26 (96.3) 19 (70.4) 22 (81.5) 26 (96.3)
a P values for differences in seroprevalence between age groups (Fisher’s test) were 0.388, 0.001, 0.001, 0.382, 0.001, and 0.001 for the Orissa plain and forest
groups and the Manhic¸a rDBL, MSP-1, EBA-175, and AMA-1 groups, respectively.
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Orissa forest areas (32) and Manhic¸a (14). This suggests that
antibodies to DBL represent a marker of age-acquired im-
munity against P. falciparum.
Our observations are in agreement with the concept of rap-
idly developing antibody responses against conserved epitopes
in PfEMP1 DBL domains in spite of their extreme polymor-
phism (24, 34). The finding that one-half of the 2.5- to 5-year-
old children from Mozambique recognized rDBL suggests
that they were exposed frequently, and possibly early in life, to
parasites expressing PfEMP1 variants with epitopes similar to
those contained in the recombinant protein. This may suggest
that the R29 var1-encoded DBL minimal domain contains
conserved epitopes which transcend sequence diversity (6, 22,
24). Whether antibodies targeting such epitopes of DBL con-
fer protection against P. falciparum malaria remains to be
determined.
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